Phase 1 trial for EBC-129 progresses into dose expansion

FHS
May 24, 2024
4:32 pm

The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

Zealand drug hit with CRL for ultra-rare disease amid manufacturing concerns, plans to resubmit in 2024

The FDA rejected Zealand Pharma’s glucagon receptor agonist in congenital hyperinsulinism (CHI) after identifying problems at a third-party manufacturing site. The company said it remains

December 29, 2023

Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for a type of blood cancer — a concession that competition

January 4, 2024

Common dietary supplement could protect against chronic Cryptosporidium infections

Researchers at the Francis Crick Institute have discovered that a common dietary supplement could protect against chronic Cryptosporidium infections which are particularly prevalent in children

December 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.